NDA 211723 · Epizyme INC
Tazverik
Tazemetostat Hydrobromide · Oral
NovelAccelerated approvalPriority reviewOrphanDiscontinuedLast checked: Nov 20, 2026Latest source record: Aug 13, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Jan 23, 2020
Approved uses
1
Original approval plus efficacy supplements
Registered trials
3
0 Phase 3, 0 recruiting
FAERS reports
1,622
721 serious, 216 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 29, 2026.
TAZVERIK is a methyltransferase inhibitor indicated for the treatment of: Adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. ( 1.1 ) Adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies. ( 1.2 ) Adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options. ( 1.2 ) These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). 1.1 Epithelioid Sarcoma TAZVERIK is indicated for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies ( 14.1 )]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). 1.2 Relapsed or Refractory Follicular Lymphoma TAZVERIK is indicated for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies. TAZVERIK is indicated for the treatment of adult patients with R/R FL who have no satisfactory alternative treatment options. These indications are approved under...
Mechanism: Tazemetostat is an inhibitor of the methyltransferase, EZH2, and some EZH2 gain-of-function mutations including Y646X, A682G, and A692V. Tazemetostat also inhibited EZH1 with a half-maximal inhibitory concentration (IC 50 ) of 392 nM, approximately 36 times higher than the IC 50 for inhibition of EZH2. The most well-characterized function of EZH2 is as the catalytic subunit of the polycomb repressive complex 2 (PRC2), catalyzing mono-, di-, and trimethylation of lysine 27 of histone H3. Trimethylation of histone H3 leads to transcriptional repression. SWItch/Sucrose Non-Fermentable (SWI/SNF)...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 23, 2020 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLetterLabelReview
1 products under this application
- TAZVERIK · TAZEMETOSTAT HYDROBROMIDE EQ 200MG BASE · TABLET, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Tazemetostat Hydrobromide" as an intervention, any sponsor and status, largest first.
National Cancer Institute (NCI)NIH
NCT05353439 · 22 participants · Start Jul 27, 2022 · Primary completion Feb 11, 2026
Drug: Pembrolizumab; Tazemetostat Hydrobromide and 1 more · For: Extensive Stage Lung Small Cell Carcinoma; Limited Stage Lung Small Cell Carcinoma; Platinum-Resistant Lung Small Cell Carcinoma and 3 more
Sites: Los Angeles, California; Newport Beach, California; Sacramento, California · 15 sites in all
- Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual TreatmentActive, not recruiting
National Cancer Institute (NCI)NIH
NCT04557956 · 16 participants · Start Aug 19, 2021 · Primary completion Oct 15, 2025
Drug: Dabrafenib Mesylate; Tazemetostat Hydrobromide and 1 more · For: Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Melanoma
Sites: Aventura, Florida; Coral Gables, Florida; Deerfield Beach, Florida · 17 sites in all
Eric Jacobsen, MDAcademic, hospital or other
NCT06692452 · 0 participants · Start Dec 24, 2024 · Primary completion Oct 1, 2027
Drug: Tazemetostat; Doxorubicin and 7 more · For: Lymphoma; Peripheral T Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma and 2 more
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use335
- fatigue326
- disease progression305
- nausea235
- product dose omission issue212
- death132
- diarrhoea123
- decreased appetite97
- vomiting95
- asthenia83
- constipation80
- headache74
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2017 | 3 |
| 2018 | 11 |
| 2019 | 6 |
| 2020 | 81 |
| 2021 | 256 |
| 2022 | 395 |
| 2023 | 316 |
| 2024 | 205 |
| 2025 | 242 |
| 2026 | 107 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
To Be Discontinued · updated Mar 27, 2026
Tazverik, Tablet, 200 mg (NDC 72607-100-00). Discontinuation of the manufacture of the drug product
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Tazverik (Tazemetostat Hydrobromide)
2024 spending
$25.1M
Beneficiaries
228
1,417 claims
Per beneficiary
$110,237
$81.67 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,816,560 |
| 2021 | $8,150,727 |
| 2022 | $14,801,232 |
| 2023 | $18,985,929 |
| 2024 | $25,134,062 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib.
Proudman D, Nellesen D, Gupta D, et al. · Adv Ther 2022 · Systematic Review, Research Support, Non-U.S. Gov't
Sponsor: Epizyme INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.